Jerry Durso was promoted to CEO last month, part of a broader shakeup in Intercept's leadership
Intercept shakeup continues as CMO, former NASH chief resigns. Is the NASH biotech abandoning its flagship disease?
First, they said goodbye to their founding CEO after 18 years. Now, Intercept is losing its CMO too, an executive who led the company’s flagship NASH program for much of its clinical development.
Intercept revealed in an SEC filing Monday that Jason Campagna tendered his resignation and will leave the company on March 5. His departure comes three months after the company abruptly announced they were replacing longtime CEO Mark Pruzanski with COO and former Sanofi commercial chief Jerry Durso.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters